



## Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
 Representative: Sunao Manabe, Representative Director, President and CEO  
 (Code no.: 4568, First Section, Tokyo Stock Exchange)  
 Please address inquiries to Junichi Onuma,  
 Vice President, Corporate Communications Department  
 Telephone: +81-3-6225-1126  
<https://www.daiichisankyo.com>

### **Daiichi Sankyo Announces Taking Over Astellas Pharma Products in Asia**

**Tokyo, Japan (October 15, 2019)** – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced agreement with Astellas Pharma Inc. (hereafter, Astellas Pharma) for the transfer to Daiichi Sankyo of three products in six Asian countries by Astellas Pharma local subsidiaries.

The products to be transferred from Astellas Pharma and the countries where they are sold are as follows.

Product [generic name (brand name)]		Korea	China	Taiwan	Thailand	Philippines	Indonesia
Ramosetron (Nasea)	Antiemetic	○			○	○	○
Nicardipine (Perdipine)	Antihypertensive	○	○	○			
Barnidipine (Oldeca)	Antihypertensive	○					

\*○ indicate the countries where the products are sold

The antiemetics are expected to have synergistic effects with mirogabalin and cancer drugs that we are developing in Asia, and two antihypertensives are expected to effectively utilize our sales base in combination with our cardiovascular products (e.g., olmesartan and edoxaban). The total net sales of Astellas Pharma's three products are approximately 5.6 billion yen (fiscal 2018).

From December 2019 onwards, Daiichi Sankyo will take over the rights and obligations including manufacturing and marketing approvals for each of the products. The manufacturer, LTL Pharma Co., Ltd., will supply them for sale in Asia by Daiichi Sankyo's local subsidiaries and other companies. Daiichi Sankyo will pay a consideration of 9.6 billion yen to Astellas Pharma for the products taken over. In order to ensure continuous supplies of the products to patients, both companies will cooperate to facilitate the

transfer of manufacturing and marketing approval in the target countries.

Daiichi Sankyo is strengthening its presence in Asia as one of initiatives to increase regional value in line with the market characteristics in each region, and we will further contribute to medical care in Asia by acquiring these product businesses.

**About Daiichi Sankyo**

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: [www.daiichisankyo.com](http://www.daiichisankyo.com).